written on 04.06.2014

Singles vs. Home Runs: Biopharmas Face a Changing ‘Paying’ Field


Amid all the dealmaking and financing talks at this year’s Allicense meeting, one topic continually returned to the surface: the increasingly dicey area of reimbursement. One has had only to follow the market trends of the past couple of months, watching as Gilead Sciences Inc.’s stock led the sudden downturn, with many industry observers attributing […]